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Alzheimer’s disease (AD) is characterized by severe basal forebrain cholinergic deficit, which 
results in progressive and chronic deterioration of memory and cognitive functions. Similar to 
acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic 
neurotransmission. Its enzymatic activity increases with the disease progression, thus classifying BChE 
as a viable therapeutic target in advanced AD. Potent, selective and reversible human BChE inhibitors 
were developed. The solved crystal structure of human BChE in complex with the most potent inhibitor 
reveals its binding mode and provides the molecular basis of its low nanomolar potency. Additionally, 
this compound is noncytotoxic and has neuroprotective properties. Furthermore, this inhibitor 
moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning 
abilities of mice in a model of the cholinergic deficit that characterizes AD, without producing acute 
cholinergic adverse effects. Our study provides an advanced lead compound for developing drugs for 
alleviating symptoms caused by cholinergic hypofunction in advanced AD.
Alzheimer’s disease (AD) is a complex neurodegenerative disorder that is characterized by progressive and 
chronic deterioration of memory and other cognitive functions. This disease leads to death within 3 years to 
9 years after diagnosis, and as the leading cause of dementia, it affects 44 million people worldwide1.
Even though the etiology of AD is very complex, several conditions are known to participate in the associated 
neurodegeneration. Accumulation of amyloid β peptide (Aβ ) deposits2,3, abnormal modification and accumu-
lation of the protein tau4 accompanied with oxidative stress in the brain lead to synaptic dysfunction and neu-
rodegeneration1. This most severely affects the cholinergic system5 and results in a decrease in the levels of the 
neurotransmitter acetylcholine (ACh)6, which in turn produces memory and cognitive deficits7, characteristic 
for patients with AD. Cholinergic neurotransmission in the brain is terminated by the hydrolysis of ACh, which 
is catalyzed by two cholinesterases (ChEs): acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)8. In 
the brain of healthy adults, AChE accounts for 80% of the ChE activity, with BChE accounting for the remainder9.
As long as AD cannot be prevented, symptomatic treatment is essential. Three out of the four approved drugs 
for treatment of patients with AD are ChE inhibitors: the selective reversible AChE inhibitors donepezil10 and 
galantamine11, and the pseudo-irreversible dual ChE inhibitor rivastigmine12 (Fig. 1a). These drugs exploit ChE 
inhibition to alleviate the symptoms of AD, or to temporarily slow down its progression, by restoring the cho-
linergic activity in the brain. However, inhibition of AChE in the peripheral nervous system and the parasympa-
thetic autonomic nervous system represents the basis for the adverse side effects (e.g., nausea, vomiting, diarrhea, 
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tremors)13, and also limits the doses14 of these drugs that can be administered. Additionally, the clinical efficacy 
of this drug class is mostly limited to mild and moderate stages of AD15,16.
The assumed co-regulatory function of BChE in termination of cholinergic neurotransmission in the 
healthy brain changes in brains of patients with progressive AD. In specific brain regions of these patients enzy-
matic activity of BChE is increased7. Increased BChE activity7 in addition to reduced expression of neuronal 
AChE in advanced AD9, findings that AChE knockout mice are viable and develop a primitive cholinergic neu-
ronal network with BChE acting as a surrogate for AChE and taking over the hydrolysis of ACh in the brain17, 
along with the fact that BChE knockout mice show no physiological disadvantages18, have led to the hypothesis 
that BChE takes over the ChE activity in advanced AD, and thus needs to be inhibited to restore the brain 
levels of ACh17. In line with this hypothesis, in aged rats, selective inhibition of BChE with cymserine analogs 
raises ACh levels in the brain and improves cognitive performance19 without any adverse parasympathetic side 
effects13. Altogether, these data suggest that BChE is a potential therapeutic target for restoring ACh levels in 
the brain and thus improving cognitive impairment, while also minimizing adverse effects in patients with 
progressive AD.
Figure 1. ChE inhibitors and structures of huBChE and its active site gorge. (a) Structures and IC50 values 
against the ChEs of the currently approved drugs for the treatment of AD symptoms that exploit ChE inhibition 
(donepezil, galantamine, rivastigmine) and selective huBChE inhibitors (bisnorcymserine and compound 1). 
(b) The overall structure of huBChE (PDB code 4TPK) shown as a green cartoon with the key amino acids 
of the active site shown as sticks. (c) The active site gorge of huBChE shown as a gray surface. The principal 
contributors to the peripheral site (Asp70; blue), the choline-binding site (Trp82; orange), the catalytic triad 
(Ser198, Glu325, His438; red), and the acyl-binding pocket (Trp231, Leu286, Val288; gray) are shown as sticks.
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Although a number of structurally diverse selective reversible and pseudo-irreversible BChE inhibitors have 
been reported19–25, cymserine analogs are the only BChE inhibitors with reported in-vivo activity19, and one 
of them has successfully advanced to Phase I clinical trials: bisnorcymserine (Fig. 1a). Cymserine analogs are 
pseudo-irreversible carbamate inhibitors, the mechanism of action of which involves a rapid initial covalent reac-
tion between their carbamate carbonyl group and the catalytic serine in the active site of ChEs (carbamoylation), 
followed by a slower regeneration (decarbamylation) of the active enzyme26. Pseudo-irreversible inhibitors are 
thus reversible covalent inhibitors, and since they derive their activity by forming a covalent bond with their 
target, concerns remain over their potential nonspecific or off-target reactivity-based toxicities27,28. In-vivo active 
selective reversible BChE inhibitors are thus highly desirable not only as potential clinical candidates for improv-
ing memory and cognitive deficits in patients with progressive AD, but also as molecular tools for studying the 
potential of BChE as a therapeutic target. The structures of human BChE (huBChE) and its active site gorge are 
shown in Fig. 1b,c.
Recently, a novel piperidine-3-ylmethanamine–based selective huBChE inhibitor 1 was reported (Fig. 1a) that 
shows reversible, slow–tight binding inhibition of huBChE with low nanomolar IC5029. This inhibitor was used 
here as the starting point for the design, synthesis, and biochemical evaluation of a comprehensive series of sulfo-
namides. The most potent of these, compound 2, shows selective reversible nanomolar huBChE inhibition with a 
new binding mode, as revealed by the crystal structure of its complex with huBChE. Furthermore, compound 2 
improves memory, cognitive functions, and learning abilities of mice in a model that mimics the symptoms of AD 
caused by cholinergic hypofunction, without producing acute cholinergic adverse effects.
Results
Design and synthesis of inhibitors. Our quest for novel sulfonamide BChE inhibitors began before the 
crystal structure of hit compound 1 in complex with huBChE was solved. Thus, the initial design efforts were 
based solely on the chemical structure of hit compound 1, which made it imperative that this design and synthesis 
yielded compounds with drug-like properties30 and good synthetic tractability.
The bioisosteric replacement of a carboxamide with a sulfonamide group is a common design strategy in 
medicinal chemistry that has been used to improve biological activity, bioavailability, and metabolic stability of 
drug candidates31. Accordingly, the type I inhibitor was designed by replacing the carboxamide group of com-
pound 1 with a sulfonamide group. Additional types of inhibitors were designed to study the effects of these 
structural modifications on the inhibitory potencies against huBChE. The naphthalene moiety was truncated and 
replaced with various substituted phenyl rings (type II inhibitors). Analogously, the 2,3-dihydro-1H-inden moi-
ety was replaced with various benzyl rings (type III inhibitors), and the importance of the N-alkyl chain on the 
sulfonamide nitrogen of these inhibitors was studied by its removal or replacement with linear alkyl substituents 
(type IV inhibitors). Finally, 1,4-disubstituted piperidine derivatives (type V inhibitors) were designed to deter-
mine the effects of a piperidine ring disubstitution pattern (Fig. 2). In conjunction with this, a synthesis route was 
planned that provided the simple and rapid generation of new inhibitors. Details regarding the synthesis of all of 
the 41 inhibitors are given in Supplementary Figures 1 to 5.
In-vitro ChE inhibition and structure–activity relationships. The inhibitory potencies against 
huBChE and murine AChE (mAChE) were determined for all of these synthesized compounds using the method 
of Ellman32. mAChE was chosen as the surrogate for huAChE on the basis that the distribution of the amino-acid 
residues along the active site gorge of these two enzymes is strictly conserved33. Table 1 gives the inhibitory 
Figure 2. Design of sulfonamide analogs of hit compound 1. The modifications introduced during each 
design step are indicated in red.
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potencies (i.e., IC50 values, % residual activities [RAs]) and structures of the most potent of these type I–V inhibi-
tors (2–6), and for a comparison, those of initial hit compound 1. The complete list of all 41 sulfonamides is given 
in Supplementary Table 1. Briefly, these IC50 values against huBChE ranged from 4.9 nM to 8270 nM, and all of 
these compounds showed significant selectivity towards huBChE over mAChE. Bioisosteric replacement of car-
boxamide in hit compound 1 with sulfonamide in the type I inhibitor (compound 3) slightly reduced the inhibi-
tory potency against huBChE. When the naphthalene ring of the type I inhibitor compound 3 was replaced with 
substituted phenyl rings (e.g., type II inhibitors), the inhibitory potencies against huBChE dropped significantly. 
The naphthalene ring was therefore retained, and the left-hand side of the type I inhibitor structure illustrated in 
Table 1 was modified further. The replacement of 2,3-dihidro-1H-inden ring with benzyl groups yielded type III 
inhibitors, among which compound 2 was the most potent inhibitor of the series, with an IC50 of 4.9 nM against 
huBChE. The type IV inhibitors revealed that variations in the N-alkyl substituent on the sulfonamide nitrogen 
were permitted for maintained inhibitory potency against huBChE, although its removal was not (Table 1 and 
Supplementary Table 1). Additionally, introduction of substituents to the benzyl and naphthalene rings of type 
III and type IV inhibitors were not tolerated for inhibitory activity against huBChE (Supplementary Table 1). 
Type V inhibitors showed that 1,3 disubstituted piperidines were more potent huBChE inhibitors than their 1,4 
disubstituted counterparts (Table 1 and Supplementary Table 1).
Chiral HPLC resolution and kinetic evaluation of compound 2. Compound 2 was resolved into its 
pure enantiomers using semi-preparative reversed-phase chiral HPLC (Fig. 3a and Supplementary Methods). 
Inhibitor type Cna Pdsb X R R1 R2
IC50 ± SEM 
(nM)
%RAc at 
10 μM ± SEM
IC50 (nM) or %RAc,d 
at 10 μM ± SEM
huBChE mAChE
Initial hit 1 1,3 CO (CH2)2OMe 21 ± 2 0.95% ± 0.56% 102100 ± 2500 nM
Type I 3 1,3 SO2 (CH2)2OMe 53 ± 4 1.47% ± 1.54% 72% ± 1%
Type II 4 1,3 SO2 (CH2)2OMe 197 ± 8 2.34% ± 0.13% 90% ± 0.003%
Type III 2 1,3 SO2 (CH2)2OMe 4.9 ± 0.3 0.40% ± 0.77% 97% ± 2%
Type IV 5 1,3 SO2 (CH2)3OMe 14.4 ± 0.8 0.71% ± 0.66% 95% ± 5%
Type V 6 1,4 SO2 (CH2)3OMe 19.3 ± 3.7 0.93% ± 0.27% 95% ± 4%
Table 1.  Inhibitory potencies and structures of hit compound 1 and the most potent of the type I to V  
inhibitors. aCn = compound number. bPds = piperidine disubstitution pattern. cRA = residual activity. 
d%RA > 75% was considered as no inhibition.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:39495 | DOI: 10.1038/srep39495
The optical purities of the enantiomers were determined by measurement of the optical rotation (Supplementary 
Methods) and by determination of the enantiomeric excess (e.e.) using analytical reversed-phased chiral HPLC 
(Fig. 3b,c, and Supplementary Methods). Both of these enantiomers were obtained with e.e. 97%. The inhibitory 
potencies of these separated enantiomers were evaluated, whereby eutomer (−)-2 had an IC50 of 4.5 nM and was 
a 3.4-fold more potent huBChE inhibitor than the distomer (+)-2 (IC50 = 15.3 nM). Given the affinity of com-
pound (−)-2 for its target enzyme huBChE, standard methods for Ki determination (e.g., Lineweaver-Burk plots) 
or approximation (e.g., Cheng-Prusoff equations) are inappropriate, as i) the target enzyme huBChE does not 
obey the typical Michaelis-Menten kinetics34 and ii) the concentration of the inhibitor is approaching the enzyme 
concentration (50 and 8.2 nM, respectively) in the assay system. This situation is referred to as tight binding inhi-
bition. Given these facts, in order to obtain the true affinity of the pure enantiomers of compound 2, the enzyme 
kinetics experiments were carried out in a stopped-flow apparatus, according to Copeland’s guidelines for eval-
uation of tight-binding inhibitors35. The full progress curves of product formation were followed in the absence 
and presence of each pure enantiomer of 2 (Fig. 3d). Of note, a high enzyme concentration was used in order to 
investigate the time-dependent inhibition and to reach the plateau of the reaction, which allowed precise quan-
tification of the substrate concentration. No curvature in the initial phase of the inhibited enzyme reaction was 
observed, indicating that the compound 2 does not display slow-binding inhibition. The curves were analyzed 
simultaneously using the ENZO application36. Several inhibition mechanisms were tested, and the single-step 
competitive mechanism allowed full reproduction of the progress curves (Fig. 3e). The inhibition constants of 
1.29 nM and 2.01 nM were determined for the enantiomers (−)-2 and (+)-2, respectively. The determined rates 
and the calculated dissociation constants for each of these enantiomers, along with the Km and kcat values for buty-
rylthiocholine iodide, are given in Supplementary Table 2. The low degree of stereoselective inhibition provided 
an advantage for compound 2, as it enabled the use of the readily available synthetic racemic mixture in further 
in-vitro and in-vivo studies.
Figure 3. Chiral HPLC resolution of racemic compound (±)-2 into pure enantiomers, and their kinetic 
evaluation. (a) Semi-preparative reversed-phase HPLC of racemic compound (±)-2 (Supplementary Methods 
[method A; 254 nm]). (b) Analytical reversed-phase chiral HPLC of (+)-2 (Supplementary Methods [method B; 
254 nm]). (c) Analytical reversed-phase chiral HPLC of (−)-2 (Supplementary Methods [method B; 254 nm]). 
(d) Progress curves for hydrolysis of 44 μ M butyrylthiocholine iodide by huBChE in the absence (E0) and 
presence of 50 nM of each pure enantiomer of compound 2 (as indicated). Data were obtained using a stopped-
flow apparatus. (e) A competitive single-step inhibition mechanism with fast association (high k2, k4) for each 
pure enantiomer fully reproduced the progress curves obtained. S, substrate; P, product; E, enzyme; EA, acylated 
enzyme; I, (−)-2; K, (+)-2; k0–k5, kinetic constants.
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Crystal structures of huBChE in complex with compounds 2, 7, and 8. The crystallographic struc-
tures of huBChE in complex with compounds 2 [-(CH2)2-OMe], 7 (-H), and 8 (-Me) were solved. These com-
pounds differ only in terms of the presence and nature of their N-alkyl group (Fig. 4a), and hence share a similar 
binding modes for huBChE (Fig. 4b and Supplementary Figure 6). Specifically, the positively charged nitrogen of 
their piperidine moiety engages in cation-π interaction with the Tyr332 side chain, while the attached benzyl ring 
fits into a groove contributed by Tyr82, Tyr332, Trp430, and Tyr440 side chains, in the choline-binding pocket. 
The naphthalene moiety is T-stacked (i.e., π -π interaction) to Trp231 in the acyl-binding pocket, while one of the 
sulfonamide oxygens forms a H-bond to the hydroxyl oxygen of Thr120 (Fig. 4c and Supplementary Figure 1). 
The -(CH2)2-OMe (compound 2) or methyl (compound 8) side chains point out of the gorge (Fig. 4b). This bind-
ing mode was not expected, given that the -(CH2)2-OMe side chain of hit compound 1 (Fig. 4a), which served as 
the scaffold for the design of these sulfonamide inhibitors, is instead oriented toward the choline-binding pocket 
(Fig. 4d)28. This phenomenon can be explained by the different hydrogen-bonding and geometrical preferences 
of the carboxamide (compound 1) and sulfonamide (compound 2) groups37. Furthermore, a H-bond is observed 
between the ether oxygen of compound 2 and a structural water, which is itself H-bonded to Asn68. The position 
of this oxygen appears to be important for the affinity of compound 2, as the additional methylene group in the 
N-alkyl chain [(CH2)3OMe] of compound 5 resulted in a 3-fold higher IC50 against huBChE than for compound 2 
(Table 1). As observed already in the complex structure of huBChE with compound 128, no conformational change 
is undergone by the enzyme upon binding of compounds 2, 7, and 8. This observation suggests that the active site 
of huBChE is fairly rigid upon binding and that tailor-made compounds are required to achieve potent huBChE 
inhibition. The larger binding surface and the greater surface complementarity (Supplementary Table 3) indeed 
correlate with higher affinity (Supplementary Table 1). The 2mFo–DFc electron density map of compound 2  
bound in the active site of huBChE is shown in Supplementary Figure 7. As both the R and S enantiomers of 
these sulfonamide inhibitors provided a fit to the electron density maps, all of the inhibitors were assigned to 
the R-enantiomers, on the basis of a possible cation-π interaction between the positively charged nitrogen of the 
piperidine moiety and the side chain of Tyr332, which is not possible for S-enantiomers.
Inhibition of BChE in rat brain slices. To investigate whether compound 2 can efficiently inhibit BChE in 
an environment that is more similar to in-vivo conditions, inhibition of BChE in rat brain slices was performed. 
Figure 4. Crystal structures of huBChE in complex with compounds 2, 7, and 8. (a) Two-dimensional 
structures of the co-crystalized sulfonamides 2, 7, and 8 and hit compound 1. (b) Alignment of crystal 
structures of compounds 2 (purple), 7 (green), and 8 (cyan) in their complexes with huBChE (gray surface). 
These inhibitors fully occupy the acyl-binding and choline-binding pockets with their naphthalene and benzyl 
moieties, respectively. (c) The polar interactions of compound 2 (purple sticks) with the amino-acid residues 
of the huBChE active site (blue) contribute significantly to the binding affinity. The observed H-bond between 
Thr120 and the sulfonamide moiety is shown as yellow dashes (distance, 3.1 Å). Compound 2 forms cation-π 
and π -π aromatic interactions with Tyr332 and Trp82, respectively. (d) Alignment of crystal structures of 
compound 2 (purple) and hit compound 1 (white) in their complexes with huBChE (white surface). PDB codes: 
5DYW (compound 2), 5DYY (compound 7), and 5DYT (compound 8).
www.nature.com/scientificreports/
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To detect the regions with the highest BChE activities in the rat brain, these were mapped and processed using a 
modified Koelle-Karnovsky histochemical method38. The dark brown/black granular BChE reaction product was 
mainly associated with glial cells, and vascular and neuronal structures. Most of the BChE-positive neurons were 
in the thalamus, neocortex, and amygdala, while very few were detected in the striatum and hippocampus, which 
is in agreement with previously published studies39,40. The highest BChE activity was detected in the laterodorsal 
thalamic nucleus, and the sections containing this region were further used in the inhibition experiments. There 
was significant reduction in the dark brown/black BChE reaction product that was formed when these sections 
were incubated with 300 μ M compound 2 (Fig. 5).
Cytotoxicity and neuroprotective effects of compound 2. Prior to any in-vivo investigations, the 
cytotoxicity profiles of compound 2 on the human liver cancer HepG2 (Supplementary Figure 8a) and neuro-
blastoma SH-SY5Y (Supplementary Figure 8b) cell lines were determined. The LD50 value for compound 2 with 
HepG2 cells was 58.67 μ M, and with SH-SY5Y cells, 31.40 μ M. These LD50 values were almost 12,000-fold and 
> 6,400-fold greater, respectively, than the concentrations needed to achieve 50% in-vitro inhibition of huBChE.
Neurotoxicity induced by Aβ species (mainly Aβ (1–42)) is a contributor to the pathogenesis of neurodegenera-
tion in AD41. To determine whether compound 2 can protect neuronal cells from toxic Aβ -species, comparisons 
were made of the neuronal death induced by Aβ (1–42) in the absence and presence of various concentrations of 
compound 2. As shown in Supplementary Figure 8c, treatment of SH-SY5Y cells with 5 μ M Aβ (1–42) caused sig-
nificant toxicity, whereas a clear dose-response neuroprotective effect was observed when the cells were exposed 
to Aβ (1–42) in the presence of compound 2. Indeed, at 10 μ M, this BChE inhibitor reversed Aβ (1–42)-induced cell 
death. The neuroprotective effects of compound 2 are independent of Aβ (1–42) aggregation as 10 μ M compound 2 
did not inhibit Aβ (1–42) aggregation (Supplementary Table 4).
In-vitro pharmacokinetics of compound 2. Since permeability values (Papp) of compounds in Caco-2 
cells (heterogeneous human epithelial colorectal adenocarcinoma cells) correlate well with in-vivo permeation42, 
simple in-vitro bidirectional permeability measurements in these cells are used to predict the absorption in 
humans43. Caco-2 cells are also used to investigate a compounds transport mechanisms43, as they express mem-
brane transport proteins like P-glycoprotein or breast cancer resistance protein (BCRP)44, which actively efflux 
drugs42. The Papp of compound 2 was determined in both directions, in eliminatory [basolateral-to-apical (B–A)] 
and absorptive [apical-to-basolateral (A–B)], and the efflux ratio [Papp(B–A)/Papp(A–B)] was calculated. The Papp(B–A) 
of compound 2 (29.1 ± 2.9) × 10−6 cm s−1, was “high” according to the biopharmaceutical classification sys-
tem of drug permeability since it is comparable to those of antipyrine, naproxen, propranolol and theophylline 
Figure 5. Inhibition of BChE in rat brain slices. Representative coronal section from a rat brain in the region 
of the thalamus processed for BChE histochemical staining using 4 mM butyrylthiocholine iodide (BTCI), in 
the absence (left) and presence (right) of 300 μ M compound 2. Here, 10 mM BW-284C51 (BW) was added to 
completely block AChE activity. Vascular structures in the cortex (black oval highlight) and BChE-rich neurons 
in the laterodorsal thalamic nucleus (black box highlight) in the absence (a,c) (respectively) and presence (b,d) 
(respectively) of compound 2. Magnification, 10× . The relative optical density (ROD) scores for the staining 
intensity for BChE activity are shown on the right.
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previously measured in the same experimental setting in the same laboratory45. In the opposite direction the 
Papp(A–B) was (30.0 ± 10.7) × 10−6 cm s−1 which results in an efflux ratio (PB–A/PA–B) of 0.97 and demonstrates that 
compound 2 is not subject to any significant active efflux mechanisms46.
10 mM compound 2 was incubated with human blood plasma to determine its plasma protein binding. 
Equilibrium dialysis showed that compound 2 is 96% protein bound (Supplementary Table 5), which is higher 
than the threshold of 90%, above which a compound is classified as highly protein bound47.
The in-vitro metabolic stability was studied by performing incubations of compound 2 in the presence of 
human blood plasma to determine the plasma half-life and with human cryoperserved hepatocytes (0.7 million 
viable cells/mL) to determine the intrinsic hepatic metabolic clearance. The plasma metabolic stability and 
hepatic clearance were estimated by the substrate depletion method. Qualitative aspect of metabolic degradation 
was performed by metabolite identification using LC-high resolution mass spectrometry (HRMS). We deter-
mined that the in-vitro half-life of compound 2 in human plasma was > 120 min (Supplementary Table 6), 
while its hepatic metabolism assessed by cryoperserved hepatocytes was more pronounced (t1/2 = 54 min) 
(Supplementary Table 7). This half-life of compound 2 is comparable to other high extraction ratio reference 
compounds cleared by CYP enzymes that were used in the metabolic stability experiment as positive controls 
(Supplementary Table 7). The marked hepatocyte clearance (18.2 μ L/min/million cells) (Supplementary Table 7) 
of compound 2 is in agreement with the three possible metabolites identified with LC-HRMS: N-debenzylated, 
demethylated, and a demethylated + glucoronide products (Supplementary Figure 9 and Supplementary Table 8).
In-vivo blood plasma–brain distribution of compound 2. Partition into the brain is essential for com-
pounds designed to be active in the central nervous system, and the most reliable evaluation of this crossing of 
the blood–brain barrier (BBB) by any molecule comes from direct in-vivo measurements of the distribution 
between the blood plasma and the central nervous system42. The distribution of compound 2 between the blood 
plasma and the brain was therefore measured in 3-month-old female Wistar Han rats, using liquid chromatog-
raphy combined with tandem mass spectrometry (LC-MS/MS) for the analysis. One hour after these rats had an 
intraperitoneal (IP) injection of 10 mg kg−1 compound 2, or 2 mg kg−1 donepezil (positive control), or vehicle 
(negative control), they were euthanized, and blood samples were collected and the brain tissue was isolated. The 
methods developed for the preparation of the blood plasma and the brain tissue included homogenization, cen-
trifugation, and solid-phase extraction for preparation of the samples for LC-MS/MS quantification (Methods, 
Supplementary Methods).
Using a validated UHPLC-MS/MS method (Supplementary Methods), the mean ± SEM concentration of com-
pound 2 in the brain tissue was determined as 78 ± 7 μ g kg−1, while that in the blood plasma was 168 ± 10 μ g L−1. 
The brain-to-plasma ratio of compound 2 was thus 0.44. This procedure was verified using the donepezil positive 
control, which provided a brain-to-plasma ratio of 6.3, which is in agreement with previous reports48. This lower 
BBB permeability of compound 2 did not prevent us from carrying out further investigates into this compound. 
High BBB permeability is essential for acute treatments, e.g., analgesics for acute pain, and it is of lesser impor-
tance for chronic administration schedules, e.g., ChE inhibitors for AD, where even compounds with modest 
permeability can produce significant pharmacological effects42.
Among the major reason for limited brain exposure of compounds designed to be active in the central nerv-
ous system is their low passive permeability combined with active efflux by membrane transport proteins like 
P-glycoprotein or breast cancer resistance protein (BCRP) and high molecular weight42. The results of permeabil-
ity measurments with Caco-2 cells show that neither low passive permeability nor active efflux are likely not the 
reason for the relatively modest brain-to-plasma ratio of compound 2. This could be due to its molecular weight 
(453 Da), which is considered borderline high for favorable distribution into the brain42.
In-vivo activity of compound 2. Passive avoidance task. The first behavioral test performed was the 
passive avoidance (PA) task, which allows the evaluation of the effects of a drug on fear-motivated contextual 
memory. This is one of the most frequently used behavioral methods to measure the effects of drug candidates on 
cognitive abilities in rodents49. In the passive avoidance task, better memory performance is determined accord-
ing to a longer step-through latency in the retention trial (i.e., the testing phase) than in the acquisition trial 
(i.e., the conditioning phase). Comparison of the retention trial step-through latencies in scopolamine-treated 
and vehicle-treated mice (23, 178 s, respectively; Fig. 6a) demonstrated the amnesic effect of scopolamine on 
learning and memory. Administration of compound 2 before scopolamine led to significant prolongation of 
the step-through latencies at each dose tested (10, 20, 30 mg kg−1, for latencies of 70, 58, 102 s, respectively). 
Administration of 1 mg kg−1 and 2.5 mg kg−1 rivastigmine also prolonged the step-through latency (85, 99 s, 
respectively), while 0.5 mg kg−1 rivastigmine was not active (Fig. 6a). As compound 2 was tested in-vivo for the 
first time, and as no effective concentration ranges had been established before, the two further behavioral tests 
were carried out with 30 mg kg−1 compound 2.
Morris water maze task. The Morris water maze (MWM) task is a hippocampus-dependent spatial learning 
and memory task that provides insight into long-term memory through decreases in escape latency time, and 
into cognition through the measure of the overall distance travelled to reach the platform50,51. In this task the 
time taken to reach the hidden platform (i.e., the escape latency time), the distance travelled, and the mean speed 
of swimming are recorded for each experimental group. For all of the groups of mice tested, the latency times 
to reach the platform tended to decrease along with the training, according to characteristic learning curves 
(Fig. 7b–e). The amnesic effect of scopolamine was seen from day 3, with a statistically significant increase in the 
distance travelled to reach the platform (vehicle treated, 3.77 m; scopolamine treated, 8.71 m), which was more 
pronounced on day 5 (1.94, 5.40 m, respectively). Mice treated with scopolamine and compound 2 travelled 
5.38 m on day 3, and 1.69 m on day 5, which demonstrated the procognitive effect of compound 2. In comparison, 
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the mice treated with scopolamine and 2.5 mg kg−1 rivastigmine travelled 3.64 m and 1.74 m on days 3 and 5, 
respectively. This effect was also observed at the lower treatment of 1 mg kg−1 rivastigmine (day 3, 4.62 m; day 5, 
1.58 m). The mean speed of the swimming was also determined to exclude any underlying sensorimotor deficits 
Figure 6. Effects of compound 2 and rivastigmine on scopolamine-induced memory impairment in the passive 
avoidance (a) and the Morris water maze tasks (b–e). (a) Data are mean step-through latencies ± SEM (n = 9–10 
mice per group). Significance: +p < 0.05; ++p < 0.01; +++p < 0.001; ++++p < 0.001, versus scopolamine-treated 
control (in the retention phase). (b–e) Learning curves showing acquisition phase for vehicle-treated mice and 
scopolamine-treated control mice (b), scopolamine-treated control mice and scopolamine-induced memory-
impaired mice treated with 30 mg kg−1 compound 2 (c), or 1 mg kg−1 (d) or 2.5 mg kg−1 (e) rivastigmine. 
Data are mean escape latency ± SEM from four daily trials. Significance versus scopolamine-treated control: 
+p < 0.05; ++p < 0.01.
Figure 7. Effects of compound 2 and rivastigmine on scopolamine-induced memory impairment in the 
two-day radial arm water maze task. Spatial learning deficits expressed as mean number of errors ± SEM in 15 
trials in five blocks (T1–T5) of three trials on day 1 (a–d) and day 2 (e–h) of the RAWM task. Vehicle-treated 
mice and scopolamine-treated control mice (a,f), scopolamine-treated control mice and scopolamine-induced 
memory-impaired mice treated with 30 mg kg−1 compound 2 (b,f), or 1 mg kg−1 (c,g) or 2.5 mg kg−1 (d,h) 
rivastigmine. Significance versus scopolamine-treated control mice: +p < 0.05; +++p < 0.001.
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in the animals treated with compound 2 and rivastigmine52. Compound 2 did not reduce the mean speed of 
swimming (vehicle, 0.17 m s−1; scopolamine, 0.15 m s−1; scopolamine + compound 2, 0.16 m s−1), although 
rivastigmine decreased it (1 mg kg−1, 0.15 m s−1; 2.5 mg kg−1, 0.12 m s−1).
Two-day radial arm water maze task. The radial arm water maze (RAWM) learning and memory task is a common 
method used to study memory deficits in mice, and it combines the spatial complexity of the dry radial arm with 
the rapid learning and strong motivation observed in the MWM53,54. In this task incorrect arm entries (i.e., errors) 
are counted. The vehicle-treated mice had a mean of 4 errors during the first trial block, but < 1 error by the end 
of the first day (Fig. 7a). In comparison, by the end of the five blocks of trials, the scopolamine-treated mice had 
a mean of nearly 3 errors (Fig. 7a). Mice treated with scopolamine and either compound 2 (30 mg kg−1) (Fig. 7b) 
or rivastigmine (2.5 mg kg−1) (Fig. 7d) all finished the acquisition phase making < 1 error. Of note, the dose of 
1 mg kg−1 rivastigmine was not effective in this task (Fig. 7c,g). At the end of day two, all of the experimental 
groups completed the RAWM task with a mean performance of 1 error, with the exception of the mice treated 
with scopolamine and compound 2, which showed better performance than the other groups, by making < 1 
error in the last trial block (Fig. 7e–h).
In-vivo safety profile of compound 2. To determine the in-vivo safety profile of compound 2 and properly 
interpret the results obtained in all three behavioural tasks, the impact of this inhibitor on motor coordination, 
sensorimotor functions and locomotor activity was determined. The effects of 30 mg kg−1 and 100 mg kg−1 com-
pound 2 on motor coordination were tested with the rotarod test (Supplementary Methods). Here, compound 
2 had no impact on the motor coordination of the mice, as it did not induce motor deficits, even at 100 mg kg−1 
(Supplementary Table 9). Also, after administration of compound 2, there were no acute cholinergic adverse 
effects in the mice, even at 100 mg kg−1 compound 2. Any underlying sensorimotor deficits in the animals treated 
with compound 2 have also been excluded, as it did not reduce the mean speed of swimming in the MWM task 
(see Chapter “Morris water maze task”). Therefore, the observed transient reduction in the locomotor activity of 
mice (Supplementary Figure 9) did not appear to have any relevant impact on the data obtained in the learning 
and memory tests.
Discussion
Using the previously reported huBChE inhibitor as a starting point, a comprehensive series of 41 new sulfona-
mide analogs were designed and synthesized. Five types of inhibitors were developed that showed nanomolar to 
micromolar inhibition of huBChE. See Supplementary Discussion for details regarding the structure–activity 
relationships of the complete series of inhibitors and the discussion regarding other sulfonamide ChE inhibitors. 
The solved crystal structures of complexes with three inhibitors revealed their binding modes and represent 
an excellent basis for their further structure-based optimization. A thorough biological evaluation of our most 
potent inhibitor 2 revealed that this compound inhibits BChE activity on rat brain slices, is not cytotoxic and 
protects neuronal cells from toxic Aβ -species. In-vitro Caco-2 cell permeability of compound 2 can be classified 
as “good” according to the biopharmaceutical classification system of drug permeability. This compound is also 
highly plasma protein bound, has a half-life in human plasma longer than 2 hours, and its metabolic stability in 
cryopreserved hepatocytes is comparable to flurazepam and naloxone. Furthermore, compound 2 permeates into 
the brain of rats and we assume that its relatively modest brain-to-plasma ratio is actually quite good considering 
its molecular weight.
Since test animals with an increased brain BChE/AChE enzymatic activity ratio are currently not available, 
animals with an unaltered brain BChE/AChE enzymatic activity ratio (CD-1 Krf and C57BL/6 J mice) were used. 
Procognitive properties of compound 2, which targets the cholinergic system (BChE), were evaluated in an 
in-vivo model relevant to its mode of action. Scopolamine-induced amnesia was chosen since it is a model related 
to the cholinergic deficit that characterizes AD and is used in AD research for preclinical evaluation of cholino-
mimetics (compounds having an action similar to that of ACh)55 e.g., ChE inhibitors55–59. This model is useful for 
the evaluation of cognition-enhancing properties of ChE inhibitors without the risk of these drugs counteract-
ing with the mechanism of the model56–59. Scopolamine, a non-selective muscarinic ACh receptor antagonist is 
administrated to test subjects to induce blockade of muscarinic ACh receptors in the central nervous system60,61 
and produce cholinergic hypofunction at the pathophysiological level, and memory and cognitive deficits at the 
behavioural level55. Scopolamine thus produces memory and cognitive deficits comparable to those caused by 
the cholinergic hypofunction in AD60,61. Procognitive effects of ChE inhibitors in scopolamine-induced amnesia 
are the result of increased brain levels of ACh. ChE inhibitors interfere with the breakdown of ACh and cause its 
accumulation in the synapse, which then displaces scopolamine from muscarinic ACh receptors, and thus ame-
liorates the scopolamine-induced memory and cognitive deficits60,62.
The dose of scopolamine used to model cholinergic deficit varies among studies, with a range from 0.2 mg kg−1 
to 2 mg kg−1, depending on the behavioral assay or drug considered. In the present study, 1 mg kg−1 scopolamine 
was injected IP before the acquisition trial of each test. This resulted in clear learning impairments in the nega-
tive controls used for the three behavioral tests performed. The anti-AD drug rivastigmine, which served as the 
positive control in these in-vivo assays, was used at concentrations comparable to those used in the clinic63. This 
selection was justified by the literature data that indicate that treatments with > 2.5 mg kg−1 rivastigmine pro-
vide less ameliorating effects on scopolamine-induced cognitive deficits than those < 2.5 mg kg−1 63,64 while also 
producing significant adverse effects, including hypersalivation, intestinal hyperperistalsis, and muscle cramps 
(i.e., tremor and retraction of the hindlimbs)63.
Three behavioral tests were performed to determine whether compound 2 can attenuate the effects of sco-
polamine by increasing brain levels of ACh through selective BChE inhibition: the PA task, the MWM, and 
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the two-day RAWM tasks. These behavioral tests and their various modifications have been used recently to 
model human cognition65. Details regarding these tests and their interpretation are given in the Methods and 
Supplementary Methods. The results of all three behavioral tasks performed in-vivo show that selective revers-
ible BChE inhibition with compound 2 improved the memory, cognitive functions, and learning abilities of 
scopolamine-treated mice with an unaltered brain BChE/AChE enzymatic activity ratio. Compound 2 would 
thus be even more effective in alleviating symptoms caused by cholinergic hypofunction in advanced AD, 
in which brain BChE enzymatic activity is increased. The results also show that despite its relatively modest 
brain-to-plasma ratio, enough compound 2 partitions into the brain to ameliorate the induced memory and 
cognitive deficits.
As inhibition of ChEs in the basal ganglia, peripheral nervous system, and parasympathetic autonomic nerv-
ous system results in an excess of ACh, which is the basis for the adverse side effects of approved drugs for the 
treatment of patients with AD13, it was imperative to determine the in-vivo safety profile of compound 2. We 
found no effects of compound 2 on motor coordination when tested with the rotarod test, no sensorimotor defi-
cits in MWM task, and no acute cholinergic adverse effects in the mice, even at 100 mg kg−1. The combination 
of these properties makes compound 2 an advanced lead compound for developing drugs for alleviating symp-
toms caused by cholinergic hypofunction in advanced AD, in which brain BChE enzymatic activity is increased. 
Additionally, compound 2 is a powerful molecular tool to study BChE biology and to validate its potential as a 
therapeutic target.
Methods
Chemistry. Only the syntheses of the most potent type I–V inhibitors (i.e., compounds 2, 3, 4, 5, 6) are 
described in this section. Those for all of the novel compounds are described in the Supplementary Methods.
Synthesis of intermediates. The syntheses of intermediates 9, 10, 11, and 12 (see Supplementary Figures 1, 2, 3, 
and 5) were achieved according to the relevant literature procedures28,66.
General procedure for the synthesis of 2, 5, and 6 (see Supplementary Figures 2, 3, and 5). Amine 10, 11, or 12 (1.0 equiv.) 
was dissolved in dichloromethane (DCM) and cooled to 0 °C. The reaction mixture was stirred, and Et3N (1.0 
equiv.) was added drop-wise. After 15 min, naphthalene-2-sulfonyl chloride (1.0 equiv.) was added, and the reac-
tion mixture was allowed to warm up to room temperature and then stirred for 24 h. The reaction mixture was 
next transferred into a separating funnel, washed with water, followed by saturated aqueous NaHCO3 solution, 
dried over anhydrous Na2SO4, and evaporated. The crude product was purified by flash column chromatogra-
phy using a suitable solvent system as the eluent (see Supplementary Methods), to yield pure 2 (1.654 g, 90%), 5 
(1.565 g, 87%), and 6 (0.254 g, 86%).
General procedure for the synthesis of 3 and 13 (see Supplementary Figure 1). Compound 10 (1.0 equiv.) was sus-
pended in DCM and cooled to 0 °C. The reaction mixture was stirred, and Et3N (3.0 equiv.) was added drop-wise. 
After 15 min, naphthalene-2-sulfonyl chloride (1.0 equiv.) or 3-nitrobenzene-1-sulfonyl chloride (1.0 equiv.) was 
added, and the reaction mixture was allowed to warm up to room temperature and then stirred for 24 h. The 
reaction mixture was next transferred into a separating funnel, washed with water, followed by saturated aqueous 
NaHCO3 solution, dried over anhydrous Na2SO4, and evaporated. The crude product was purified by flash col-
umn chromatography using a suitable solvent system as the eluent (see Supplementary Methods) to yield pure 3 
(0.220 g, 93%) and 13 (0.145 g, 40%).
Synthesis of 4 (see Supplementary Figure 1). Aromatic nitro compound 13 (0.120 g, 0.253 mmol, 1.0 equiv.) was 
dissolved in a mixture of tetrahydrofuran (THF)/MeOH (1:1, v/v) and cooled to 0 °C. NiCl2 × 6H2O (0.241 g, 
1.012 mmol, 4.0 equiv.) and NaBH4 (0.172 g, 4.554 mmol, 18.0 equiv.) were added, and the resulting suspension 
was stirred at 0 °C for 2 h, and then allowed to warm up to room temperature, and stirred for an additional 16 h. 
The solvent was evaporated and DCM (15 mL) was added to the residue. The precipitated solid was filtered under 
suction, and washed with DCM (15 mL). The combined filtrates were evaporated, and the crude product purified 
by flash column chromatography using DCM/MeOH (20:1, v/v) as the eluent, to produce 0.064 g of 4 as a pale 
brown solid (57% yield).
For the inhibition of BChE in the rat brain slices, the in-vitro cytotoxicity assay, the in-vivo blood plasma to 
brain distribution assay, and the in-vivo activity assays, compound 2 was used in the form of its hydrochloride 
salt (see Supplementary Scheme S2, Supplementary Methods). All of the novel compounds were appropriately 
characterized and were of high purity (> 95%; analytical HPLC, Supplementary Methods).
Biology. In-vitro inhibitory activity against the ChEs. The inhibitory potencies of the compounds against the 
ChEs were determined using the method of Ellman32. The assay protocol and IC50 calculations are described in 
the Supplementary Methods.
Kinetic studies for huBChE inhibition. The mode of action of huBChE inhibition by pure enantiomers of com-
pound 2 was determined as previously described28. Briefly, the time-course of yellow color formation was fol-
lowed on a Bio-logic SFM-2000 stopped flow apparatus at 25 °C. The two buffer solutions were prepared as one 
that contained the substrate butyrylthiocholine iodide, the 5,5′ -dithiobis (2-nitrobenzoic acid) reagent (Ellman 
reagent), and test compound 2 (each pure enantiomer), and the other that contained huBChE. The buffer solu-
tions were injected into a mixing chamber using syringes. The resulting solution contained 44 μ M butyrylthio-
choline iodide, 1 mM Ellman reagent, 8.2 nM huBChE, 50 nM test compound, and 0.007 M DMSO (i.e., 0.05% 
v/v). The absorbance was followed immediately at 412 nm, and until the change reached zero. The progress curves 
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obtained were analyzed simultaneously, using the ENZO application36, which can derive and numerically solve a 
system of differential equations, and fit their coefficients. Several reaction mechanisms were tested. The simplest 
one for the reproduction of the progress curves in the absence and presence of (+)-2 and (−)-2 was chosen, and 
the corresponding inhibition constants were determined. The results file can be accessed by loading the ENZO 
project ID http://enzo.cmm.ki.si/kinetic.php?uwd= 151006561&load= true, selecting the ‘Set Parameters’ tab, 
and pressing ‘Start’.
Crystallization, data collection, and processing. Crystallization, data collection, and processing are described in 
Supplementary Methods.
Cell culture and treatments. The HepG2 cell line was obtained from American Type Culture Collection (LGC 
Standards, UK) and was cultured in RPMI 1640 medium (Sigma-Aldrich, St. Louis/MO, USA) supplemented 
with 10% fetal bovine serum (Gibco, Grand Island/NY, USA), 2 mM L-glutamine, 100 U mL−1 penicillin and 
100 μ g mL−1 streptomycin (all from Sigma-Aldrich) in a humidified chamber at 37 °C and 5% CO2. Compound 2 
was used at 0.625 μ M to 125 μ M, in DMSO.
Human neuroblastoma SH-SY5Y cells were obtained from American Type Culture Collection (CRL-2266, 
Manassas, VA, USA). They were grown in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis, MO) supple-
mented with 10% fetal bovine serum (HyClone, Logan, UT, USA), 2 mM L-glutamine, 50 U mL−1 penicillin and 
50 μ g mL−1 streptomycin (Sigma, St. Louis, MO, USA), in a humidified atmosphere of 95% air and 5% CO2 at 
37 °C, and grown to 80% confluence. Prior to cell treatments, complete medium was replaced with reduced-serum 
medium (i.e., with 2% fetal bovine serum). Compound 2 was prepared as a stock solution of 10 mM in DMSO 
and was used at concentrations of 1 μ M to 100 μ M. For the cytotoxic stimuli, Aβ (1–42) was dissolved in DMSO 
to give a 1 mM stock solution and 24 h prior cell treatment, the peptide was incubated at final concentration of 
5 μ M in reduced-serum medium in the absence and presence of compound 2 (1–10 μ M) at 37 °C, to induce Aβ 
aggregation. The metabolic activity and cell viability assays and the assessment of cytotoxicity are described in 
Supplementary Methods.
Aβ(1–42) aggregation inhibitory activity. The thioflavin-T (ThT) fluorometric and dot-blot assays used are 
described in Supplementary Methods.
Inhibition of BChE in rat brain slices. Animals. Adult male Wistar rats (500–600 g; The Wistar Institute, 
Philadelphia, PA, USA) were used in this study. The rats were handled according to the European Community 
Council Directive of 23 November 1986 (86/609/EEC), and the National Veterinary Institute guide for the Care 
and Use of Laboratory Animals. All efforts were made to minimize the number of rats used and their suffering.
Preparation of brain tissue. The rats were sacrificed by decapitation under CO2 anesthesia. The brain of each 
animal was rapidly removed and immediately frozen on dry-ice powder, wrapped in Parafilm to prevent desic-
cation, and stored at − 80 °C. Before cutting, the brains were allowed to equilibrate with the temperature of the 
cryostat chamber that had been adjusted to − 20 °C. Brains were cut into 16 serial sections of 20 μ m thickness 
in a coronal plane on a Leica SM2000R microtome with a Physitemp freezing stage and a BFS-30TC controller. 
The cytoarchitectonic parcellation of the brain areas was guided by the atlas of the adult rat brain by Paxinos 
and Watson67. Each section was thaw-mounted onto an RNAse-free glass slide coated with a 0.01% solution 
of (poly)L-lysine in dimethylpyrocarbonate, fixed for 5 min in 4% paraformaldehyde, and rinsed (3 × 3 min) in 
phosphate-buffered saline (PBS) with potassium. Sections were stained for BuChE or AChE using histochemical 
techniques37. The ChE histochemistry and the analysis of BuChE staining of brain structures were as described 
in the Supplementary Methods.
In-vitro pharmacokinetic of compound 2. Caco-2 monolayer bidirectional permeability assay is described in 
detail in the Supporting Methods. In solution properties, in vitro metabolism assays, and identification and char-
acterization of metabolites of compound 2 (in the form of its hydrochloride salt) when incubated with cryopre-
served human hepatocytes were performed by Eurofins Panlab (St. Charles, MO, USA), in study no. 100028035. 
In each experiment the respective reference compounds were tested concurrently with test compound 2 and 
the data were compared with historical values determined at Eurofins. The experiment was accepted in accord-
ance with Eurofins validation Standard Operating Procedure. Details on these experiments are described in the 
Supporting Information.
In-vivo blood plasma to brain distribution. Animals. The blood plasma–brain distribution of compound 2 
was measured in 3-month-old female Wistar Han rats with body weight of 220 g ± 10%. The rats were handled 
according to the European Community Council Directive of 23 November 1986 (86/609/EEC), and the National 
Veterinary Institute guide for the Care and Use of Laboratory animals. The experimental design was evaluated by 
the National Ethical Committee for Animal Experimentation and approved by the Veterinary Administration of 
the Republic of Slovenia. All efforts were made to minimize the number of rats used and their suffering.
Chemicals used in the BBB assay. Here, 10 mg mL−1 compound 2 was dissolved in 1% Tween 80 isotonized 
with sodium chloride, and sterilized by filtration. Isotonized 1% Tween 80 was used as the negative control, and 
2 mg mL−1 donepezil in the same solution was used as the positive control.
In-vivo blood plasma–brain distribution assay protocol, sample collection and work up. Four rats were given 
compound 2 and three rats were used for each of the positive and negative controls. The IP injected doses of 
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compound 2 and donepezil were 10 mg kg−1 and 2 mg kg−1, respectively. The rats were euthanized by CO2 inha-
lation 1 h after administration of compound 2. Immediately, 2 mL blood was collected in Vacutainer tubes with 
10.8 mg K2EDTA, and the brain tissue was isolated. Blood plasma was obtained after centrifugation of the blood at 
3,500 rpm for 10 min. The blood plasma and brain tissue were stored at − 20 °C until further sample preparation.
Four aliquots of approximately 150 mg of each brain tissue sample were weighted and homogenized in 2-mL 
microcentrifuge tubes (Eppendorf, Germany) with 25 μ L internal standard solution (450 μ g L−1 haloperidol in 
80% MeOH with 0.1% acetic acid), 300 μ L PBS, and 125 μ L methanol, in a blender (Bullet Blender; Next Advance, 
NY, USA) for 3 min at speed setting ‘8’ with 0.5-mm glass beads. The homogenate was centrifuged at 10,000 rpm 
for 7 min, and the supernatant was removed. The sample was mixed again in the blender for 1 min at speed setting 
‘5’, and a second supernatant was collected after centrifugation as before. These supernatants were then combined, 
and 900 μ L 2% H3PO4 was added prior to solid phase extraction (SPE).
Blood plasma aliquots (150 μ L) in 2-mL microcentrifuge tubes (Eppendorf) were mixed with 25 μ L internal 
standard solution (450 μ g L−1 haloperidol in 80% MeOH with 0.1% acetic acid), 300 μ L PBS and 125 μ L MeOH. 
The samples were mixed in the blender for 1 min at minimum speed, and sonicated in an ultrasound bath for 
5 min. Then 900 μ L 2% H3PO4 was added in two aliquots during the quantitative sample transfer to the SPE 
column.
For the preparation of all of the samples for LC-MS/MS quantification, Bond Elut Plexa PCX (30 mg, 3 mL) 
SPE columns were used. The SPE columns were conditioned with 2 mL methanol and equilibrated with 2 mL 
water before the samples were slowly loaded. Then 2 mL 2% formic acid, followed by 2 mL MeOH/MeCN mixture 
(1:1, v/v) were used for column washing. The samples were eluted with 1 mL 25% ammonia in water/MeOH/
MeCN (1:2:2, v/v), and dried for 20 min in a concentration evaporator (Turbovap) at 60 °C. The dried samples 
were stored at − 20 °C until analysis. The samples were reconstituted in 200 μ L 0.1% acetic acid in 80% MeOH 
using 2 × 2-min mixing in the blender at minimum speed, separated by a 10-min waiting interval.
For the calculation of the brain-to-plasma ratio of compound 2 its concentration in the brain which is 
given in μ g kg−1 and its concentration in blood plasma which is given in μ g L−1 the specific density of wet rat 
brain (1.05 g mL−1) was used68. LC-MS/MS analysis and LC-MS/MS method validation are described in the 
Supplementary Methods.
In-vivo activity assays. Animals. Eight-week-old male Albino Swiss (CD–1 Krf) mice weighing from 18 g to 
22 g were used in the passive avoidance task, and the locomotor activity and rotarod tests, and C57BL/6 J mice 
of the same age were used in the MWM and the RAWM tasks. The mice were housed in groups of 10 per cage at 
room temperature (22 ± 2 °C) under a light/dark (12 h:12 h) cycle. The mice had free access to food and water, and 
the ambient temperature and humidity of the room were kept constant throughout all of the tests. For the behav-
ioral tasks, the mice were selected at random, and each group consisted of 8 to 10 mice dose−1. The experiments 
were performed between 08:00 and 14:00. Immediately after these in-vivo assays, the animals were euthanized by 
cervical dislocation. The maintenance and treatment of the laboratory animals were carried out in full accordance 
with the guidelines issued by the Local Ethics Committee of the Jagiellonian University in Krakow (ZI/862/2013). 
All efforts were made to minimize the number of mice used and their suffering.
Chemicals used in the in-vivo activity assays. For the in-vivo experiments, compound 2 was suspended in 1% 
Tween 80 (Polskie Odczynniki Chemiczne, Poland), with IP injections 60 min before the acquisition trial of learn-
ing and memory tasks, and the locomotor activity and rotarod tests. Rivastigmine hydrogen tartrate was from 
Sigma Aldrich (Poland), and it was dissolved in distilled water and administered by the same route as compound 2. 
Control mice were given an appropriate amount of vehicle (1% Tween 80, IP). (−)-Scopolamine hydrobro-
mide was from Sigma Aldrich (Poland). To induce memory impairment, scopolamine was dissolved in distilled 
water, with IP administration at 1 mg kg−1 30 min before the acquisition trial of each learning and memory task. 
Vehicle-treated mice were used as the negative control. For comparison, the same experiments were performed in 
mice similarly treated with scopolamine and the anti-AD drug rivastigmine, which served as the positive control 
in these in-vivo assays. The behavioral testing paradigms are described in the Supplementary Methods.
References
1. Querfurth, H. W. & LaFerla, F. M. Alzheimer’s disease. N. Engl. J. Med. 362, 329–344 (2010).
2. Glabe, C. C. In Alzheimer’s Disease: Cellural and Molecular Aspects of Amyloid β 1st edn Ch. 8 (eds Harris, J. R. & Fahrenholz, F.) 
167–177 (Springer, 2005).
3. Elsinghorst, P. W., Härtig, W., Goldhammer, S., Grosche, J. & Gütschow, M. A Gorge-spanning, high-affinity cholinesterase inhibitor 
to explore β -amyloid plaques. Org. Biomol. Chem. 7, 3940–3946 (2009).
4. Morris, M. et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. 
Neurosci. 18, 1183–1189 (2015).
5. Scherder, E. In Aging and Dementia: Neuropsychology, Motor Skills, and Pain 1st ed. Ch. 1, 9–32 (VU University Press, 2011).
6. Scarpini, E., Schelterns, P. & Feldman, H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol. 2, 
539–547 (2003).
7. Perry, E. K. et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 
2, 1457–1459 (1978).
8. Reid, G. A., Chilukuri, N. & Darvesh, S. Butyrylcholinesterase and the cholinergic system. Neuroscience 234, 53–68 (2013).
9. Giacobini, E. In Treatment of Dementias: A New Generation of Progress 1st edn Ch. 2 (eds Meyer, E. M., Simpkins, J. W., Yamamoto, 
J. & Crews, F. T.) 19–34 (Springer, 1992).
10. Sugimoto, H., Iimura, Y., Yamanishi, Y. & Yamatsu, K. Synthesis and structure-activity relationships of acetylcholinesterase 
inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 
38, 4821–4829 (1995).
11. Greenblatt, H. M., Kryger, G., Lewis, T., Silman, I. & Sussman, J. L. Structure of acetycholinesterase complexed with 
(− )-galanthamine at 2.3 A resolution. FEBS Lett. 463, 321–326 (1999).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:39495 | DOI: 10.1038/srep39495
12. Bar-On, P. et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. 
Biochemistry 41, 3555–3564 (2002).
13. Hartmann, J. et al. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by 
butyrylcholinesterase activity. J. Neurochem. 100, 1421–1429 (2007).
14. Ballard, C., Greig, N., Guillozet-Bongaarts, A., Enz, A. & Darvesh, S. Cholinesterases: roles in the brain during health and disease. 
Curr. Alzheimer Res. 2, 307–318 (2005).
15. Wilkinson, D. G., Francis, P. T., Schwam, E. & Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer’s 
disease: The relationship between pharmacological effects and clinical efficacy. Drugs Aging 21, 453–478 (2004).
16. Hansen, R. A. et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A 
systematic review and meta-analysis. Clin. Inter. Aging 3, 211–225 (2008).
17. Mesulam, M. M. et al. Acetylcholinesterase knocouts establish central cholinergic pathways and can use butyrylcholinesterase to 
hydrolyze acetylcholine. Neuroscience 110, 627–639 (2002).
18. Li, B., Duysen, E. G., Carlson, M. & Lockridge, O. The butyrylcholinesterase knockout mouse as a model for human 
butyrylcholinesterase deficiency. J. Pharmacol. Exp. Ther. 324, 1146− 1154 (2008).
19. Greig, N. H. et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer 
β -amyloid peptide in rodent. Proc. Natl. Acad. Sci. 102, 17213–17218 (2005).
20. Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K. & Kling, A. Oral tetrahydroaminoacridine in long-term treatment of 
senile dementia, Alzheimer type. N. Engl. J. Med. 315, 1241–1245 (1986).
21. Decker, M. Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterase with dirigible selectivity towards 
butyrylcholinesterase. J. Med. Chem. 49, 5411–5413 (2006).
22. Rizzo, S. et al. Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, β amyloid aggregation, and Aβ 
neurotoxicity. J. Med. Chem. 51, 2883–2886 (2008).
23. Darvesh, S. et al. Carbamates with differential mechanism of inhibition toward acetycholinesterase and butyrycholinesterase. J. Med. 
Chem. 51, 4200–4212 (2008).
24. Carolan, C. G. et al. Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective 
butyrylcholinesterase inhibitor. J Med Chem 53, 1190–1199 (2010).
25. Zha, X. et al. Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: 
design, synthesis, biological evaluation, and X-ray crystallography. J. Med. Chem. 59, 114–131 (2016).
26. Bartolucci, C., Stojan, J., Yu, Q., Greig, N. H. & Lamba, D. Kinetics of Torpedo californica acetylcholinesterase inhibition by 
bisnorcymserine and crystal structure of the complex with its leaving group. Biochem. J. 444, 269–277 (2012).
27. Copeland, R. A. In Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists 1st ed. 
Ch. 8, 214–248 (John Wiley & Sons, 2005).
28. Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307–317 (2011).
29. Brus, B. et al. Discovery, biological bvaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. 
J. Med. Chem. 57, 8167–8179 (2014).
30. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).
31. Ciapetti, P. & Giethlen, B. In The Practice of Medicinal Chemistry 3rd edn Ch. 15 (ed. Wermuth, C. G.) 290–342 (Academic Press, 
2008).
32. Ellman, G. L., Courtney, K. D., Andres, jr. V. & Featherstone, R. M. A new and rapid colorimetric determination of 
acetylcholinesterase activity. Biochem. Pharmacol. 7, 88–95 (1961).
33. Kryger, G. et al. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom 
toxin fasciculin-II. Acta Crystallogr. D Biol. Crystallogr. 56, 1385–1394 (2000).
34. Stojan, J. et al. Concentration-dependent reversible activation-inhibition of human butyrycholinesterase by tetraethylammonium 
ion. Eur. J. Biochem. 269, 1154–1161 (2002).
35. Copeland, R. A. In Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists 2nd ed. 
Ch. 7, 245–285 (John Wiley & Sons, 2013).
36. Bevc, S. et al. ENZO: A web tool for derivation and evaluation of kinetic models of enzyme catalyzed reactions. PLoS One 6, e22265 
(2011).
37. Ramesh, V. V. E. et al. Carboxamide versus sulfonamide in peptide backbone folding: a case study with a hetero foldamer Org. Lett. 
15, 1504–1507 (2013).
38. Koelle, G. B. & Friedenwald, J. A. A histochemical method for localizing cholinesterase activity. Proc. Soc. Exp. Biol. Med. Soc. Exp. 
Biol. Med. 70, 617–622 (1949).
39. Darvesh, S., Grantham, D. L. & Hopkins, D. A. Distribution of butyrylcholinesterase in the human amygdala and hippocampal 
formation. J. Comp. Neurol. 393, 374–390 (1998).
40. Geula, C. & Nagykery, N. Butyrylcholinesterase activity in the rat forebrain and upper brainstem: postnatal development and adult 
distribution. Exp. Neurol. 204, 640–657 (2007).
41. Giordano, C. R., Terlecky, L. J., Bollig-Fischer, A., Walton, P. A. & Terlecky, S. R. Amyloid-beta neuroprotection mediated by a 
targeted antioxidant. Sci. Rep. 4, 1–9 (2014).
42. Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem. 58, 2584–2608 
(2015).
43. Hubatsch, I., Ragnarsson, E. G. E. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 
monolayers. Nat. Protoc. 2, 2111–2119 (2007).
44. Sun, H., Chow, E. C., Liu, S., Du, Y. & Pang, K. S. The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin. Drug. Metab. 
Toxicol. 4, 395–411 (2008).
45. Žakelj, S., Berginc, K., Roškar, R., Kraljič, B. & Kristl, A. Do the recommended standards for in vitro biopharmaceutic classification 
of drug permeability meet the “passive transport” criterion for biowaives? Curr. Drug Metab. 14, 21–27 (2013).
46. Di, L. & Kerns, E. H. Transporter Methods. In Drug–Like Properties: Concepts, Structure, Design, and Methods from ADME to 
Toxicity Optimization 2nd edn Ch. 27, 339–350 (Academic Press, 2016).
47. Fesce, R. & Fumagalli, G. Drug Distribution and Ellimination. In General and Molecular Pharmacology: Principles of Drug Action 1st 
edn Ch. 5, (eds Clementi, F. & Fumagalli, G.) 45–60 (Wiley, 2015).
48. Geerts, H. et al. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res. 
1033, 186–193 (2005).
49. Gulcan, H. O. et al. Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-
benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorg. Med. Chem. 22, 5141–5154 (2014).
50. Patil, S. S., Sunyer, B., Höger, H. & Lubec, G. Evaluation of spatial memory of C57BL/6J and CD1 mice in the Barnes maze, the 
Multiple T-maze and in the Morris water maze. Behav. Brain Res. 198, 58–68 (2009).
51. Puzzo, D., Lee, L., Palmeri, A., Calabrese, G. & Arancio, O. Behavioral assays with mouse models of Alzheimer’s disease: Practical 
considerations and guidelines. Biochem. Pharmacol. 88(4), 450–467 (2014).
52. Vorhees, C. V. & Williams, M. T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. 
Protoc. 1, 848–858 (2006).
www.nature.com/scientificreports/
1 5Scientific RepoRts | 6:39495 | DOI: 10.1038/srep39495
53. Alamed, J., Wilcock, D. M., Diamond, D. M., Gordon, M. N. & Morgan, D. Two-day radial-arm water maze learning and memory 
task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat. Protoc. 1, 1671–1679 (2006).
54. Sudduth, T. L., Weekman, E. M., Brothers, H. M., Braun, K. & Wilcock, D. M. β -amyloid deposition is shifted to the vasculature and 
memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res. Ther. 6, 
32 (2014).
55. Van Dam, D. & De Deyn, P. P. Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 5, 956–970 (2006).
56. Bouger, P. C. & van der Staay, F. J. Rats with scopolamine- or MK-801-induced spatial discrimination deficits in the cone field task: 
animal models for impaired spatial orientation performance. Eur. Neuropsychopharmacol. 15, 331–346 (2005).
57. van der Staay, F. J. & Bouger, P. C. Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced 
impairments in the spatial cone field orientation task in rats. Behav. Brain Res. 156, 1–10 (2005).
58. Stemmelin, J., Cassel, J. C., Will, B. & Kelche, C. Sensitivity to cholinergic drug treatments of aged rats with variable degrees of spatial 
memory impairment. Behav. Brain Res. 98, 53–66 (1999).
59. Vardigan, J. D. et al. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil 
and xanomeline in rhesusmonkey. Psychopharmacology (Berl). 232, 1859–1866 (2015).
60. Ebert, U. & Kirch, W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance Eur. J. Clin. 
Invest. 28, 944–949 (1998).
61. Bajo, R. et al. Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer’s disease. Sci. Rep. 5, 1–6 
(2015).
62. Snyder, P. J., Bednar, M. M., Cromer, J. R. & Matuff, P. Reversal of scopolamine-induced deficits with a single dose of donepezil, an 
acetylcholine inhibitor. Alzheimer’s & Dementia 1, 126–135 (2005).
63. Zhang, W. W. et al. Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive 
amelioration of rivastigmine. J. Neural Transm. (Vienna) 116, 1643–1649 (2009).
64. Bejar, C., Wang, R. H. & Weinstock, M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur. J. 
Pharmacol. 383, 231–240 (1999).
65. Zhang, J. et al. BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory 
impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. Eur. J. Pharmacol. 613, 1–9 
(2009).
66. Košak, U., Brus, B. & Gobec, S. Straightforward synthesis of orthogonally protected piperidin-3-ylmethanamine and piperidin-4-
ylmethanamine derivatives. Tetrahedron Lett. 55, 2037–2039 (2014).
67. Paxinos, G. & Watson, C. In The Rat Brain in Stereotaxic Coordinates 2nd edn (Academic Press, 1986).
68. DiResta, G. R. et al. Measurment of Brain Tissue Density Using Pycnometry. In Brain Edema VIII 1st edn Ch. 12, (eds Reulen, H. J., 
Baethmann, A., Fenstermacher, J., Marmarou, A. & Spatz, M.) 34–36 (Springer, 2015).
Acknowledgements
This work was supported by the Slovenian Research Agency, the France-Alzheimer Foundation, the Agence 
Nationale de la Recherche (ANR), and Institut Francais. We thank Marielle Vandhammer and Marie Trosvalet for 
providing us with lyophilized murine AChE and human BChE, as well as for continuous and fruitful discussions. 
We thank Domen Kutoša, Urša Jarc, Julija Lipušček, Aljoša Jelenko, Matevž Černigoj and Jure Breznik for their 
contributions. We thank Dr. Dušan Žigon (Jožef Stefan Institute, Ljubljana, Slovenia) for performing the mass 
spectrometry measurements. We also thank Dr. Chris Berrie for critical reading of the manuscript.
Author Contributions
U.K. participated in the design of the inhibitors, performed the chemistry, in-vitro ChE inhibition assays and 
chiral HPLC resolution. B.B. participated in the design of the inhibitors, performed in-vitro ChE inhibition 
assays, chiral HPLC resolution, inhibition kinetics studies, experiments on rat brain slices, and participated in 
the crystallographic studies. D.K. participated in the design of the inhibitors, performed the chemistry, in-vitro 
ChEs inhibition assays and the Aβ (1–42) aggregation inhibitory activity assays. R.Š. performed the chemistry. 
S.Ž. participated in the in-vivo blood plasma–brain distribution assay, performed the work up and the LC-MS/
MS analysis of samples obtained in the in-vivo blood-brain barrier permeation assay and performed the in-vitro 
permeability assay with Caco2 cells. J.T. performed the work up and LC-MS/MS analysis of samples obtained 
in the in-vivo blood-brain barrier permeation assay. A.P. performed the cytotoxicity and neuroprotecitivity 
assays with SH-SY5Y cells. J.Š. performed the cytotoxicity and neuroprotecitivity assays with SH-SY5Y cells. 
M.G. performed the cytotoxicity assays with HepG2 cells. M.Ž. performed assays of inhibition of BChE on 
rat brain slices and the in-vivo blood plasma–brain distribution assays. L.T. performed in vivo blood plasma–
brain distribution assays. M.P. performed in vivo blood plasma–brain distribution assays. K.S. performed and 
analyzed data from the in-vivo activity assays. A.P. participated in performance and analysis of the in-vivo 
activity assays. B.F. worked on the data from the in-vivo activity assays. F.N. prepared and purified the huBChE. 
X.B. prepared and purified the huBChE. A.W. participated in in-vivo activity assays. B.M. participated in 
in-vivo activity assays. J.S. performed inhibition kinetic studies. I.M.R. oversaw the cytotoxicity assays with 
HepG2 cells. J.K. oversaw the cytotoxicity and neuroprotecitivity assays with SH-SY5Y cells. N.C. performed 
crystallographic studies. J.P.C. oversaw the crystallographic studies. S.G. conceived and oversaw the project. 
All of the authors contributed to the design, analysis and discussion of the research and the writing of the 
manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Košak, U. et al. Development of an in-vivo active reversible butyrylcholinesterase 
inhibitor. Sci. Rep. 6, 39495; doi: 10.1038/srep39495 (2016).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 6Scientific RepoRts | 6:39495 | DOI: 10.1038/srep39495
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
